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Our previous work demonstrates that DHX32 is upregulated in colorectal cancer (CRC) compared to its
adjacent normal tissues. However, how overexpressed DHX32 contributes to CRC remains largely
unknown. In this study, we reported that DHX32 was overexpressed in human colon cancer cells.
Overexpressed DHX32 promoted SW480 cancer cells proliferation, migration, and invasion, as well as
decreased the susceptibility to chemotherapy agent 5-Fluorouracil. Furthermore, PCR array analyses
revealed that depleting DHX32 in SW480 colon cancer cells suppressed expression of WISP1, MMP7 and
VEGFA in the Wnt pathway, and anti-apoptotic gene BCL2 and CA9, however, elevated expression of
pro-apoptotic gene ACSL5. The findings suggested that overexpressed DHX32 played an important role in
CRC progression and metastasis and that DHX32 has the potential to serve as a biomarker and a novel
therapeutic target for CRC.
C
olorectal cancer (CRC) is one of the leading causes of cancer-related deaths with high morbidity and
mortality1. The high mortality nature of colon cancer is due to its sporadic origin and diagnosed at
advanced stages. 5-Fluorouracil (5-FU) has been used for more than 40 years in treating various cancers
and remains as the standard first-line chemotherapeutic drug for CRCs, although as high as 50% of metastatic
CRCs resist to 5-FU-based chemotherapies2–4. Therefore, understanding the molecular basis of genetic and
epigenetic changes that contribute to CRC progression and the targets of 5-FU in CRC are important for
developing new therapeutic strategies and for overcoming drug resistance.
RNA helicases are members of the DExD/H-box family, which are characterized by the presence of a helicase
domain and are involved in RNAmetabolism5,6. In addition to their roles in RNAmetabolism, multiple members
of the DExD/H-proteins are also implicated in transcription regulations, including RNA helicase A (DHX9)7 and
p68 (DHX5)8,9. Several of RNAhelicases are dysregulated in cancer cells, although the exact contributions of RNA
helicases to cancer initiation and progression have not been fully characterized10,11. DHX32 is originally identified
as a novel RNA helicase with the unique helicase domain12. DHX32 has a widespread tissue distribution. Human
and murine DHX32 exhibits a high similarity in the amino acid sequences, suggesting that it is a functionally
important and well-conserved gene12,13. However, the functions of DHX32 are largely unknown. We reported
previously that the expression ofDHX32 is up-regulated inCRCs compared to its adjacent normal tissues and that
the level of DHX32 expression is associated with cancer location, lymph gland metastasis, cancer nodal status,
differentiation grade, and Dukes’ stage14. In this study, we investigated the function of DHX32 in CRC cells and
systematically examined gene expression profile changes in major signal transduction pathways affected by
depleting DHX32. The data showed that DHX32 promoted proliferation, migration, and invasion of CRC cells,
as well as reduced sensitivity for 5-FU treatment. Furthermore, our data also showed that DHX32 upregulated the
Wnt pathway and downregulated pro-apoptotic gene expression. The results suggested the potential of DHX32 as
a biomarker for CRC diagnosis and as a novel target for CRC treatment.
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Results
Upregulated expression of DHX32 in human CRC cells. RNA
helicase DHX32 is highly expressed in human CRC compared to
its adjacent normal tissues14. To further study whether DHX32 was
also overexpressed in human CRC cells, quantitative real-time RT-
PCR (Fig. 1a) andWestern blot (Fig. 1b) analyses were carried out to
assess the expression of DHX32 in human CRC cell lines SW480,
HCT-8, LS174T and SW620, as well as normal human colonic
epithelial cell lines NCM460 and CCD-18Co at the mRNA level
and protein level, respectively. Consistent with our previous report
in human colorectal cancer samples, expression of DHX32 at both
the mRNA and protein levels was higher in human CRC cells than in
normal human colonic epithelial cells.
Overexpression of DHX32 promotes proliferation of CRC cells. To
unravel the role of DHX32 in CRC tumorigenicity, DHX32 was
depleted or overexpressed by stable expression of DHX32 specific
shRNA or full-length DHX32 cDNA, respectively. Both real-time
RT-PCR and Western analyses demonstrated that expression of
DHX32 was reduced by shRNA or increased by cDNA transfection,
respectively (Fig. S1).
To determine whether the expression level of DHX32 affected
CRC cell proliferation, the Cell Counting Kit-8 (CCK-8) was
employed to assess CRC cell growth with or without depletion or
overexpression of DHX32. The results showed that the DHX32-
depleted cells exhibited a decreased growth rate compared to that
of control cells, whereas overexpression of DHX32 increased cell
proliferation (Fig. 2a&2b). Consistently, colony formation assays
demonstrated that the number of colonies was increased in
DHX32-overexpressed and reduced in DHX32-depleted SW480 cell
groups (Fig. 2c&2d). The results suggest that DHX32 contributes to
proliferation and colony formation of CRC cells.
Overexpressed DHX32 reduces 5-FU induced apoptosis in CRC
cells. To determine whether depletion or overexpression of DHX32
affects cell viability, the cells were labeled with anti-Annexin V and 7-
AAD and then subjected to fluorescent assisted cell sorting (FACS)
analyses. The results clearly demonstrated that neither over-
expression nor depletion of DHX32 changed apoptotic cell
population in SW480 cells. It has been shown that DHX32
desensitize T-cells from responding to apoptotic stimuli15. 5-FU is
a commonly used apoptosis-inducing drug in CRC treatment. To
investigate whether DHX32 protected CRC undergoing apoptosis
induced by 5-FU, SW480 cells were treated with 5-FU in the
culture medium. As expected, 5-FU induced notable changes in
cell morphology and density, especially in DHX32-depleted cells.
In order to assess the cell numbers at different apoptotic stages, the
cells were stained with anti-Annexin V and 7-AAD, the early and late
apoptotic markers, respectively. As shown in Figure 3a, treating
SW480 cells with 5-FU resulted in an increase in apoptosis.
Depletion of DHX32 increased both Annexin V and 7-AAD
labeled cell populations, whereas overexpression of DHX32
reduced both cell populations (Fig. 3b).
To further assess the involvement of DHX32 in 5-FU induced
apoptosis, we analyzed apoptosis-related protein poly ADP-ribose
polymerase (PARP) expression in 5-FU treated cells. Indeed, deple-
tion of DHX32 expression increased the cleavage of PARP in 5-FU
treated SW480 cells (Fig. 3c), and overexpression of DHX32 dimin-
ished the cleavage of PARP in 5-FU treated SW480 cells (Fig. 3d).
Taken together, the results demonstrate that although the expression
level of DHX32 per se does not affect cell apoptosis, it modulates the
response to apoptotic reagents in CRC cells although the underlying
molecular mechanism remains to be unveiled.
DHX32 enhances migration and invasion of CRC cells. To
determine whether the expression level of DHX32 affected cell
motility, the scratch wound-healing assay was carried out. As shown
in Fig. 4a and Fig. S2a, the scratch gap in the control cells was almost
half-closed within 48 hours. However, the scratch gap in the DHX32-
depleted cells was not closed even at day 3. In contrast, DHX32-
overexpressed clones displayed more cells in the gap than in the
control cells (Fig. 4b & Fig. S2b). Similarly, the Transwell assay also
demonstrated that depletion of DHX32 compromised cell migration
activity (Fig. 4c & Fig. S2c), whereas DHX32 overexpression resulted
in enhancing transmembrane migration activity of the cells (Fig. 4d &
Fig. S2d). Furthermore, the transwell Matrigel invasion assay also
showed that depletion of DHX32 expression reduced invasion
activities (Fig. 4e & Fig. S2e) and overexpression of DHX32
enhanced the invasion activity of SW480 cells (Fig. 4f & Fig. S2f).
Together, the results demonstrate that DHX32 contributes to the
migration and invasion activities of CRC cells.
DHX32 contributes to the regulation of genes important for cell
migration and apoptosis. To gain insight into the molecular
mechanism by which DHX32 contributed to tumorigenicity of
CRC, a SA Biosciences 96-well Signal Transduction Pathway
Finder PCR Array plate with pre-coated primer pairs was used to
detect gene expression changes of 10 commonly studied signal
transduction pathways. The microarray analysis was carried out
with DHX32-depleted cells and control cells. Scatter plot depicting
expression profiles of all the 84 tested genes in DHX32-depleted
versus control cells was displayed in Figure 5a. The genes that
exhibited at least twofold increases or reduces were indicated by
colored circles. The expression profiles validated by real-time RT-
PCRwere shown in Figure 5b. Notably, DHX32 depletion attenuated
expression of 5 genes. Among them, WISP1 (WNT-inducible
signaling pathway protein 1), MMP7 (matrix metallopeptidase 7),
Figure 1 | DHX32 is overexpressed in CRCs compared to normal human
colonic epithelial cell. Expression of DHX32 was determined with real-
time RT-PCR (a) or western blot (b) analyses (the blots were cropped, and
the full-length blots were included in the supplementary information).
Note that DHX32 expression was higher in SW480, HCT-8, LS174T, and
SW620 than inNCM460 and CCD-18Co cells. b-actin levels were used as a
loading control.
www.nature.com/scientificreports
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and VEGFA (vascular endothelial growth factor A) are within the
Wnt pathway. Additionally, the anti-apoptotic genes Bcl-2 (B cell
leukemia/lymphoma 2) and CA9 (carbonic anhydrase IX) were
downregulated 4 and 10 fold respectively in DHX32-depleted cells
compared to control cells. In contrast, ACSL5 gene expression was
increased in DHX32 depleted cells, which was implicated in the
activation of PPAR. Therefore, the gene expression profile changes
suggest a positive roles ofDHX32 in cell proliferation, migration, and
invasion possibly via activation of the Wnt signaling pathway and a
negative role in apoptosis.
Discussion
With a few exceptions, the biochemical activities and biological roles
of RNA helicases, including DHX32, are not very well characterized.
Our previous work shows that DHX32 is up-regulated in CRC com-
pared to its adjacent normal tissues and the level of DHX32 express-
ion is associated with the progression of CRC14. In this report, we
further demonstrated that expression of DHX32 was elevated in
human CRC cells at both mRNA and protein levels. We also showed
that upregulation of DHX32 promoted CRC cell proliferation,
migration, and invasion, as well as inhibited apoptosis. The data
indicate that upregulation of DHX32 favors CRC progression and
metastasis.
There are examples of dysregulation of human RNA helicase
expression in various types of cancer16. Furthermore, it has been
suggested that RNA helicase can either regulate the activity with or
without direct interactions with the molecules that are implicated in
cancer. Among them, DDX5,DHX9 andDDX17 have been shown to
be involved in transcription regulation17–19. To date, however,
although several reports have shown that DHX32 contributes to
cancer development, themolecularmechanism underlying the onco-
genic activities of DHX32 are still elusive.
In this study, we utilized the RT2 profilerTM PCR Array to deter-
mine the specific signaling pathways and the gene expression
profiles that were regulated by DHX32. It was found that multiple
genes overexpressed in CRC cells were downregulated by deple-
tion of DHX32 expression. Among the 10 signaling pathways
analyzed, the most notable changes were in the Wnt signaling
pathway. Wnt signaling is a well-characterized pathway that pro-
motes progression and metastasis in many types of cancers.
Aberrant activation of the Wnt pathway, either through the gen-
etic or epigenetic alterations, has been found to contribute to
tumorigenesis. In fact, it has been reported that aberrant Wnt
signaling is an early progression event in 90% of CRC20–23. As
described in the Results section, we observed that depletion of
DHX32 down-regulated WISP1, MMP7 and VEGFA expression
at the mRNA level, implying that DHX32 contributed to CRC
progression through upregulating the Wnt pathway. Our results
also suggested that DHX32 promoted migration and invasion
activities of CRCs. The results are in accordance with our previous
report that the upregulated expression of DHX32 in colorectal
cancer tissues is associated with lymph gland metastasis14.
Figure 2 | DHX32 increases proliferation and colony formation of CRC cells. (a&b), DHX32 expression level is associated with cell proliferation of
SW480 cells. DHX32 depleted (a) or overexpressed (b) and the control SW480 cells were cultured for 24, 48, 72, and 96 hours. The cell density was
then determinedwith the CCK-8Assay Kit as described inMethods. (c&d), DHX32 expression level is associated with colony formation activity of SW480
cells. Cell colonies derived fromDHX32 depleted (c) or overexpressed (d) SW480 cells were counted. Data are mean 6 SD from triplicated samples. NC,
vector only transfectant as a negative control; *P,0.05, **P,0.01.
www.nature.com/scientificreports
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Figure 3 | DHX32 reduces 5-FU induced apoptosis in CRC cells. (a&b), Annexin V labeling based flow cytometry analyses of apoptotic cells. DHX32
depleted and control SW480 (a) were subjected to 20 mM 5-FU treatment. DHX32 overexpressed and negative control SW480 (b) were subjected to
40 mM 5-FU treatment. Apoptotic cells were detected with a flow cytometry at 48 hours after the treatment. Early and late stages of apoptosis were
identified as Annexin V1/7-AAD2 and Annexin V1/7-AAD1, respectively. (c&d), Western blot analyses showed that the PARP cleavage was increased in
DHX32 depleted (c) or decreased inDHX32 overexpressed (d) SW480 cells at 36 hours after being treated with 5-FU (the blots were cropped, and the full-
length blots were included in the supplementary information). NC, vector only as a negative control; **P,0.01.
www.nature.com/scientificreports
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In addition, our data showed that depletion of DHX32 in CRC
cells increased expression of pro-apoptotic molecule ACSL-5 and
reduced anti-apoptotic molecules Bcl-2 and CA9. Several studies
show that ACSL-5 is expressed in mitochondria and its activities
are associated with increased susceptibility of apoptosis and cell
death pathways24,25. Recent studies also reveal that Bcl-2 is related
to mitochondria-apoptotic regulation and modulation26,27. CA9 is
overexpressed in a wide variety of human cancers. Inhibition of
CA9 decreases cell proliferation and induces apoptosis28,29. DHX32
is the first putative RNA helicase in the DHX family that is localized
in the mitochondria13. The mitochondria residence of DHX32 sug-
gests a potential role of DHX32 inmitochondria-mediated apoptosis
through processing mitochondrial RNA.
5-FU is widely used in treating CRC. However, cancer cells fre-
quently evade drug-induced death signals. As a result, chemoresis-
tance is the major impediment of 5-FU-based therapies. Therefore,
to identify new molecular targets for 5-FU treatments will provide
new approaches to increase 5-FU efficacy for CRC treatment. Recent
studies showed that the Wnt pathway plays an important role in
chemotherapy resistance of various malignancies30,31. Our data
showed that overexpression of DHX32 in CRCs protected the cells
from cell death induced by 5-FU. Interestingly, we also noticed that
5-FU treatment decreased DHX32 expression at the mRNA and
protein levels in a dose-dependent manner (Fig. S3). Thus, concur-
rently treating the patients with 5-FU andDHX32 inhibitors can be a
viable option for CRC chemotherapies.
In conclusion, this is the first report demonstrating that DHX32
promotes cell proliferation, migration, and invasion, as well as
reduces sensitivity to chemotherapy reagents in CRC, viamodulating
expressions of gene involved in cancer cell growth, migration, and
survival. It is worthy to determine whether DHX32 can be used as a
novel target for CRC treatment in conjunction with other chemo-
therapy reagents.
Methods
Cell culture and reagent. Human colorectal cell CCD-18Co and human colorectal
carcinoma LS174T cell were grown in high-glucose Dulbecco’s modified Eagle’s
medium (DMEM, Gibco), and human colorectal cell NCM460 and human CRC
SW480, SW620, and HCT-8 cells were grown in the RPMI-1640 medium (Gibco),
with supplements of 10% (v/v) fetal bovine serum (Gibco) and 100 units/ml
streptomycin and penicillin (Millipore), at 37 uC.
Figure 4 | DHX32 promotes CRC cells migration and invasion. (a&b),
Scratch wound assays for DHX32 depleted (a) or overexpressed (b) SW480
cells. The average sizes of the gapsweremeasured at the indicated times and
expressed as mean 6 SD of triplicated samples. (c&d), Transwell chamber
assays for DHX32 depleted (c) or overexpressed (d) SW480 cells. The
average numbers of migrated cells were counted after 24-hour incubations
and expressed as mean 6 SD. (e&f), Transwell Matrigel invasion assays for
DHX32 depleted (e) or overexpressed (f) SW480 cells. The average
numbers of migrated cells were quantitated after 24-hour incubations and
expressed as mean 6 SD. NC, vector only as a negative control; **P,0.01.
Figure 5 | Depleting DHX32 induces gene expression changes in SW480
cells. (a), Real-time RT-PCR analyses of gene expression with the Signal
Transduction Pathway Array from SA Biosciences. The genes with twofold
changes are plotted. Upregulated genes are shown in red, and
downregulated genes in green. (b), Real-time RT-PCR analyses for the
genes identified in the miniarray. b-actin was used as an internal loading
control. **P,0.01.
www.nature.com/scientificreports
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The chemical reagents 5-FUwas purchased fromSigma; puromycin and blasticidin
from InvivoGen. The anti-DHX32 antibody was purchased from Sigma; anti-b-actin
antibody from Santa Cruz.
DNA constructs.DHX32 expression plasmid was constructed by sub-cloning a PCR
product of human DHX32 cDNA into pLOC vector and the sequence of the cDNA
was confirmed.
For gene silencing, five independent short hairpin RNA (shRNA) targeted to
DHX32 were cloned into a pGIPZ vector. The sequences of DHX32 shRNAs are 59-
CGCCATATTCATCACGTTATTA-39 (F-1), 59-CGGTTGTTCCTTTGTATCCA-
AA-39 (B-11), 59–AAAGGAAAACACTCTAAACATA-39 (F-11), 59-AATCCACA-
ACTCTCGAAGTCTA-39 (G-8), and 59- ACCCTGTGTCAACAATGAATAA-39
(E-10).
Stable cell line generation. For establishment of stable DHX32-depleted cell line,
SW480 cells were cultured for 24 hours to 60%–80% confluence before transfected
with the DHX32-shRNA constructs using the FuGENE HD Transfection Reagent
(Promega). The pGIPZ empty vector was used as a negative control. Twenty four
hours post-transfection, the cells were selected with 2 mg/ml puromycin for two
weeks. The efficiency of the depletion was determined by real-time RT-PCR and
western blot analysis. The most efficient shRNA (G-8) was chosen to deplete DHX32
thorough out the study.
pLOC-DHX32 clone and pLOC empty vector was stably transfected using
FuGENE HD Transfection Reagent and selected with 20 mg/ml blasticidin for two
weeks. Blasticidin resistant single clones were isolated and two of these independent
clones were successfully established, which were designated as SW480-DHX32 and
SW480-NC, respectively. The DHX32 expression in these cell lines was determined
by real-time RT-PCR and western blot.
Quantitative real-time RT-PCR. Total RNA was extracted from cells using Trizol
(TIANGEN) according to the manufacturer’s protocol and the cDNA was
synthesized using the RevertAid First Strand cDNA Synthesis Kits (Fermentas).
Quantitative real-time RT-PCR was then performed using gene-specific primers as
described in our previous study14. The expression of target transcripts was normalized
to the b-actin internal control, and relative changes of gene expression were
determined using the 22DDCt method. The primers for DHX32 are 59-GTCTTTCCA-
TCCACTACCAGCAC-39 (forward) and 59-ATGATGACCCCATAGCTACCCAA-
39 (reverse); for b-actin are 59-TCACCCACACTGTGCCCATCTACGA-39
(forward) and 59-CAGCGGAACCGCTCATTGCCAATGG-39 (reverse); for ACSL5
are 59-TGGCTATCTTACAAACAGGTGTC-39 (forward) and 59-TCCACTCTGG-
CCTATTCTGAG-39 (reverse); for Bcl2 are 59-GGTGGGGTCATGTGTGTGG-39
(forward) and 59-CGGTTCAGGTACTCAGTCATCC-39 (reverse); for CA9 are 59-
GGATCTACCTACTGTTGAGGCT-39 (forward) and 59-CATAGCGCCAAT-
GACTCTGGT-39 (reverse); for MMP7 are 59- ATGTGGAGTGCCAGATGTTGC-
39 (forward) and 59- AGCAGTTCCCCATACAACTTTC-39 (reverse); for VEGFA
are 59-AGGGCAGAATCATCACGAAGT-39 (forward) and 59-AGGGTCTCGAT-
TGGATGGCA-39 (reverse); for WISP1 are 59-AGGAACTGCATAGCCTACACA-
39 (forward) and 59- TGGTACACAGCCAGACACTTC-39 (reverse).
Immunoblotting. Immunoblotting assay was carried out as described previously32.
Briefly, cells were lysed using ice-cold lysis buffer TNTE 0.5% (0.5% Triton X-100,
50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA) containing 10 mg/ml
pepstatin A, 10 mg/ml leupeptin, and 1 mM PMSF. The total cell lysates were then
applied to immunoblotting assays using appropriate antibodies and detected by
Chemiluminescent HRP substrates (Millipore). The gels in the figures have been run
under the same experimental conditions.
Cell proliferation assays. The Cell Counting Kit-8 (CCK-8) (Dojindo) was used to
measure cells proliferation. 3 3 103 SW480 cells per well were seeded in 96-well
plates and incubated for 24, 48, 72, and 96 hours, respectively. The cells were then
incubated with the CCK-8 reagent (10 ml per well) for 2 hours prior to measure the
absorbance of 450 nm with an ELISA plate reader (Thermo).
Colony formation assays. Cells were seeded in 6-well plates at a density of 500 cells
per well. After incubating for 12 days, the colonies were fixed with methanol and
stainedwithGiemsa. Only those colonies containingmore than 50 cells were counted.
Wound healing assay. Cells were seeded in 6-well plates at a density of 105 cells per
well and incubated for 24 hours. Then a 20 ml pipette tip was used to scratch a
linear wound in the cell monolayer. Photos were taken at 0, 24, 48, and 72 hours after
the scrapping, respectively.
Cell migration assay.Chemotactic migration of SW480 cells was examined using the
Transwell Chember Assay. Cells were serum-starved for 24 hours and then plated at
the density of 105 cells per well in the serum-free medium. The RPMI 1640 medium
containing 10% FBS was added into the bottom chamber as a chemoattractant. After
incubation for 24 hours, non-migrating cells were removed from the upper chamber
with a cotton swab and cells migrated through the membrane were fixed with 4%
formaldehyde and stained with crystal violet staining solutions. Cell numbers in five
randomly selected fields were counted under a microscope (Leica) with 200 3
magnification.
Matrigel invasion assay. The Matrigel Invasion chambers with 8 micron Matrigel-
coated filters (BD BioCoat) were used to study the cell invasion activity. Briefly, cells
were serum starved for 24 hours and then seeded in the upper compartment of
Matrigel-coated inserts at a concentration of 5 3 105 cells per well. The medium
containing 10% FBS was added into the bottom chamber. After incubation for
24 hours, non-invaded cells in the upper chamber were removed. Cells that invaded
through themembrane to the lower surface were counted under amicroscope (Leica)
with 200 3 magnification and photographed.
Apoptosis analysis. Cells cultured in 6-well plates were treated with the indicated
chemicals, trypsinized, and collected in 1.5 ml tubes. After centrifugation, the cells
were resuspended in 1 3 binding buffer. The cell suspensions were then used for
apoptosis analyses with the PE Annexin V Apoptosis Detection Kit (BD Biosciences)
according to themanufacturer’s instruction. After incubation at room temperature in
the dark for 15minutes, an excess of 13 binding buffer was added to a final volume of
500 ml. A total of 10,000 cells were examined by flow cytometry using a BD Influx cell
sorter (BD Biosciences). Cells were gated on side scatter and forward scatter to
exclude debris. Annexin V/7-AADdouble positive and Annexin V–positive/7-AAD–
negative cells were defined as apoptotic cells.
Gene array analysis. The Human Signal Transduction PathwayFinderTM RT2
ProfilerTM PCR Array (SA Biosciences) was used, which includes cDNAs for 84 key
representative genes of 10 signal pathways. Briefly, total RNAs were extracted from
control and DHX32 depleted cells using the RNeasy Mini kit (Qiagen) according to
the manufacturer’s protocol. RNA integrity and quality was determined prior to gene
expression analyses. For the cDNA synthesis, 5 mg of total RNA was reverse
transcribed (RT) to first-strand cDNA according to the protocol provided by the RT2
Easy First Strand Kit (SA Biosciences). The resultant cDNA was diluted and mixed
with the SA Biosciences RT2 qPCRMaster Mix and water to a total volume of 2.7 ml.
The reactionmixture (25 ml per well) was loaded into a 96well plate for real-time PCR
analyses performed on an ABI7500 (Life Technologies) PCR machine following the
instructions provided by the PCR array kit. The mRNA levels were normalized
against housekeeping genes included in the PCR array (b-glucuronidase;
hypoxanthine guanine phosphoribosyl transferase 1; heat shock protein 90 kDa a;
glyceraldehyde-3-phosphate dehydrogenase; and b-actin). Gene expression levels
were calculated using the RT2 Profiler PCR Array Data Analysis Template v3.3
software and were expressed as folds of control cells. Unsupervised clustergram/heat
mapwere generated by using the RT2 PCR array data analysis web portal (http://www.
sabiosciences.com/pcrarraydataanalysis.php).
Statistical analysis.Data are expressed as mean 6 SD of triplicate samples. The data
significance was evaluated by using Student’s t-test. P,0.05 was considered a
statistically significant difference.
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